Cardio-oncology & otherSecondary analysis
Impact of the ESC Cardio-Oncology Guidelines Biomarker Criteria on Incidence of Cancer Therapy–Related Cardiac Dysfunction
- Secondary analysis of the PRADA randomised trial
- retrospective
Authors' conclusion
Mild asymptomatic CTRCD during adjuvant breast cancer therapy was frequent and driven mainly by cTn elevation and was not prognostic of subsequent CTRCD.
Study context
- Population
- Patients receiving adjuvant breast cancer therapy in the PRADA trial
- Participants
- 118 patients
- Primary endpoint
- Cumulative incidence, point prevalence and prognostic value of CTRCD by different asymptomatic CTRCD guideline criteria (alternative cTn 99th percentile upper reference limits (URLs))
Primary result
As reported in the abstract
Cumulative incidence of CTRCD
Moderate or severe cancer therapy-related cardiac dysfunction (CTRCD)
1.7%
Mild asymptomatic CTRCD, cTnT > sex-specific 99th percentile URL
49.2%
Mild asymptomatic CTRCD, sex-neutral cTnI
9.3%
Further findings
Point prevalence of CTRCD · end of anthracycline therapy
- Highest at end of anthracycline therapy, driven primarily by asymptomatic cardiac troponin (cTn) elevation
- 47.8%
Prognostic value of CTRCD during adjuvant therapy for CTRCD at extended follow-up · 24 months (Q1-Q3: 21-29 months) after randomization
- Not prognostic
Original publication
Impact of the ESC Cardio-Oncology Guidelines Biomarker Criteria on Incidence of Cancer Therapy–Related Cardiac Dysfunction. JACC CardioOncol. Published 16 January 2024. doi:10.1016/j.jaccao.2023.10.008
Summarised from the published abstract; every number is checked against it